Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for BTA798

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug BTA798?

BTA798 is an investigational drug.

There have been 5 clinical trials for BTA798. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1^st 2010.

The most common disease conditions in clinical trials are Infections, Infection, and Respiratory Tract Infections. The leading clinical trial sponsors are Biota Scientific Management Pty Ltd, Biota Pharmaceuticals, Inc., and Aviragen Therapeutics.

Summary for BTA798

US Patents	0
International Patents	0
US Patent Applications	50
WIPO Patent Applications	22
Japanese Patent Applications	13
Clinical Trial Progress	Phase 2 (2010-08-01)
Vendors	22

Recent Clinical Trials for BTA798

Title	Sponsor	Phase
A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers	Aviragen Therapeutics	Phase 1
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection	Biota Pharmaceuticals, Inc.	Phase 2
A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers	Biota Scientific Management Pty Ltd	Phase 1

See all BTA798 clinical trials

Clinical Trial Summary for BTA798

Top disease conditions for BTA798

Top clinical trial sponsors for BTA798

See all BTA798 clinical trials

US Patents for BTA798

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck

Colorcon

Medtronic

McKesson

Harvard Business School

Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.